GILD Gilead Sciences Inc.

77.73
-0.48  -1%
Previous Close 78.21
Open 79.24
Price To Book 4.34
Market Cap 97,863,249,164
Shares 1,259,015,170
Volume 19,098,648
Short Ratio
Av. Daily Volume 23,000,494
Stock charts supplied by TradingView

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 3 trial did not meet primary endpoint - February 11, 2019.
Selonsertib (GS-4997) - STELLAR 4
Nonalcoholic steatohepatitis (NASH)
Phase 2 enrollment completed 1Q 2018.
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 2 trial did not meet primary endpoint.
Filgotinib and GS-9876
Sjogren’s syndrome
Phase 3 enrolment to be completed 2H 2020.
Cilofexor (GS-9674)
Primary sclerosing cholangitis
Phase 2 data released November 9, 2018.
GS-9674
Primary biliary cholangitis
Phase 2 trial to complete enrolment 3Q 2019.
GS-5734
Ebola
FDA Approval announced October 3, 2019.
F/TAF (Descovy)
Pre-exposure prophylaxis
Phase 2 data due 1H 2020.
Axicabtagene ciloleucel - (ZUMA-5)
Indolent B-Cell Non-Hodgkin Lymphoma
Phase 2 trial did not meet primary endpoint.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 trial to be initiated later in 2020.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 3 enrolment has been paused due to COVID-19,
Filgotinib PENGUIN
Psoriatic arthritis
Phase 3 futility analysis 3Q 2017. Trial to continue.
Andecaliximab GS-5745
Gastric Cancer
Approved February 7, 2018.
Bictegravir/F/TAF
HIV
Phase 2 data 4Q 2018.
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 3 data April 25, 2019 did not meet primary endpoint.
Selonsertib (GS-4997) - STELLAR 3
Nonalcoholic steatohepatitis (NASH)
Phase 2 data released October 24, 2017. Positive high dose data, low dose negative.
GS-0976
Nonalcoholic steatohepatitis (NASH)
Approval announced July 18, 2017.
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
Hepatitis C virus (HCV)
Phase 2 ongoing.
Entospletinib
Chronic Graft Versus Host Disease (cGVHD)
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 enrolment paused due to COVID-19.
Filgotinib - DIVERSITY
Crohn’s disease
NDA filing announced December 19, 2019.
Filgotinib
Rheumatoid arthritis (RA)
PDUFA date under priority review August 10, 2020.
Axicabtagene ciloleucel - (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2 pivotal trial enrolment completed 3Q 2019.
Axicabtagene ciloleucel - (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 1/2 data released 2Q 2019.
Axicabtagene ciloleucel - (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
2-year data at ASH 2018 noted 39% of patients were in an ongoing response. OS not yet reached.
Yescarta (axicabtagene ciloleucel)
Refractory Non-Hodgkin's Lymphoma (NHL) - cancer
Phase 1/2 data due 1H 2020.
Axicabtagene ciloleucel (ZUMA-6)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1 data due 1H 2021.
Axicabtagene ciloleucel (ZUMA-8)
Chronic lymphocytic leukemia (CLL)
Phase 3 data due 2H 2020.
Axicabtagene ciloleucel (ZUMA-7)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 2 trial did not meet primary endpoint - December 16, 2019.
Cilofexor (GS-9674) and firsocostat (GS-0976) - ATLAS
Nonalcoholic steatohepatitis (NASH)
Phase 3 trial initiated 3Q 2019.
Selonsertib (GS-4997)
Diabetic kidney disease
Phase 1 trial ongoing.
Axicabtagene ciloleucel - KTE-C19 and utomilumab (ZUMA-11)
Phase 2 trial initiated 4Q 2019.
Axicabtagene ciloleucel and rituximab/lenalidomide (ZUMA-14)
Large B-cell Lymphoma
Phase 2 data due 2021.
Axicabtagene ciloleucel - (ZUMA-12)
Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2 trial to be initiated 4Q 2019.
GS-4875
Ulcerative Colitis
Phase 3 data due April 2020.
Remdesivir GS-5734
Coronavirus / COVID-19
sNDA FDA Approval announced March 19, 2020.
Epclusa (sofosbuvir /velpatasvir)
Hepatitis C

Latest News

  1. STAT News Reporter Says CEOs Of Amgen, Genentech, Gilead And Regeneron Were Involved In Call With Trump

  2. Gilead Sciences Option Alert: Thu $80 Calls at the Bid: 500 @ $1.081 vs 11701 OI; Earnings 4/30 After Close [est] Ref=$76.45

  3. Gilead Analyst Sees Catalyst Ahead In Data Readout For Potential Coronavirus Treatment

  4. 'Data for Gilead's potential coronavirus therapy are coming soon. Here's what you need to know' -Article From STAT News

  5. Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma

    -- Kite and Teneobio will Collaborate on Next-Generation Dual-Targeting CAR T Therapies in Multiple Myeloma Utilizing UniAb® Antibodies -- Kite, a Gilead Company (NASDAQ:GILD), and Teneobio, Inc. announced the

  6. Gilead Announces Expiration of Hart-Scott-Rodino Waiting Period for Forty Seven Tender Offer

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead's cash tender offer for Forty

  7. U.S. Food And Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection

    -- Pediatric approval of protease inhibitor-free, pan-genotypic, pan-fibrotic, once-daily regimen supports HCV elimination efforts by providing critical option for broad range of populations -- Gilead Sciences, Inc.

  8. New Clinical Study Data for Gilead's Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020

    – Phase 1B Study Demonstrates the Potential of GS-6207 to Rapidly Reduce Viral Load After a Single Subcutaneous Injection – – Gilead Progresses Long-Acting Therapy Research Program to Help Address Real-World

  9. Treatment With Gilead's Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study

    -- Results Presented at CROI 2020 Support Further Evaluation of Vesatolimod as Part of Investigational Curative Regimens Aimed at Achieving ART-Free Control of HIV -- Gilead Sciences, Inc. (NASDAQ:GILD) today announced

  10. Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations

    Gilead Sciences, Inc. (NASDAQ:GILD) today presented longer-term results from the DISCOVER trial of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets, F/TAF) for pre-exposure prophylaxis (PrEP),

  11. New Data on Gilead's Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults

    – Phase 3 Data from the BRAAVE 2020 Study in Black or African American Virologically Suppressed Adults Presented, Including Patients with a History of Treatment Failure or Pre-Existing Resistance – – Analysis of

  12. New Leadership for Gilead Sciences Canada, Inc. - Melissa Koomey Appointed Vice President and General Manager

    MISSISSAUGA, ON, March 5, 2020 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada), based in Mississauga, Ontario, today announced the appointment of Melissa Koomey as Vice President and General Manager. Koomey will be

  13. Takeover Approach Rumors to Gilead Sciences – Alibaba Jack Ma & CEO Sun

    Focusing on coronavirus, negations privately taking place between GILD and Jiangsu Hengrui Medicine for Gilead Sciences 3 Patent in exchange for licensing royalty and revenue sharing generated by the

  14. Gilead to Acquire Forty Seven for $4.9 Billion

    – Gilead Gains Forty Seven's Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma – –

  15. Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19

    -- U.S. FDA Grants Investigational New Drug Authorization to Study Remdesivir for the Treatment of COVID-19 -- Gilead Sciences, Inc. (NASDAQ:GILD) today announced the initiation of two Phase 3 clinical studies to

  16. GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial

    TAMPA, FL / ACCESSWIRE / February 26, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™)

  17. Gilead Appoints Michael Quigley to Lead Research Biology Group and Names Linda Higgins as Head of Company's External Innovation Center

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Michael Quigley, PhD has joined the company as Senior Vice President, Research Biology, bringing to the role deep experience in oncology and immuno-oncology

  18. Gilead Sciences to Present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020

    Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Johanna Mercier, Chief Commercial Officer, and Merdad Parsey, MD, PhD, Chief Medical Officer, will participate

  19. U.S. FDA Grants Priority Review for Kite's KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma

    -- If Approved, Kite Could be First Company with Multiple Commercialized CAR T Therapies -- Kite, a Gilead Company (NASDAQ:GILD), today announced that the U.S. Food and Drug Administration (FDA) has accepted the

  20. Gilead Sciences Announces 8 Percent Increase In First Quarter 2020 Dividend

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 8% in the company's quarterly cash dividend, beginning in the first quarter of 2020. The increase

  21. Gilead Sciences Announces Fourth Quarter and Full Year 2019 Financial Results

    - Fourth Quarter Product Sales of $5.8 billion - - Full Year 2019 Product Sales of $22.1 billion - - Full Year 2019 Diluted EPS of $4.22 per share - - Full Year 2019 Non-GAAP Diluted EPS of $6.63 per share

  22. Sandra Horning, MD, Joins Gilead Sciences' Board of Directors

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Sandra Horning, MD, has been appointed to the company's Board of Directors. Dr. Horning retired in 2019 as Chief Medical Officer and Global Head of Product

  23. European Medicines Agency Validates Kite's Marketing Application for Company's Second CAR T Cell Therapy

    -- Investigational KTE-X19 To Be First Chimeric Antigen Receptor (CAR) T Cell Therapy for Mantle Cell Lymphoma in Europe if Approved -- -- Filing for Kite's Second CAR T Therapy Marks Potential Expansion of Company's

  24. Gilead Sciences to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 4, 2020

    -- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its fourth quarter and full year 2019 financial results will be released on Tuesday, February 4, after the market

  25. Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences

    BERKELEY, Calif., Jan. 13, 2020 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, announced today that it has raised

  26. Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that the company has licensed The Rockefeller University's portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents

  27. Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences

    Successful demonstration of preclinical in vivo proof-of-concept studies advances collaboration to develop highly specific inhibitors of TGFβ activation for the potential treatment of patients suffering from fibrotic

  28. Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval

    -- Agreement Extends to Additional Potential Indications for Filgotinib, Including Ulcerative Colitis, Crohn's Disease and Psoriatic Arthritis -- Gilead Sciences, Inc. (NASDAQ:GILD) and Eisai Co., Ltd. (Tokyo, Japan)

  29. Gilead Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020

    Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Daniel O'Day, Gilead's Chairman and Chief Executive Officer, will provide an overview of the company at the

  30. China National Medical Products Administration Approves Vosevi® (Sofosbuvir, Velpatasvir and Voxilaprevir) for People With Chronic Hepatitis C Infection Who Require Re-Treatment

    – Vosevi Provides a New Option for People with HCV Who Have Not Achieved Cure with Prior Direct-Acting Antiviral Treatment – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that the China National Medical Products

  31. Gilead Submits Filgotinib New Drug Application to U.S. Food and Drug Administration Under Priority Review for Rheumatoid Arthritis Treatment

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor

  32. Gilead submits new drug application to U.S. Food and Drug Administration under priority review for filgotinib for rheumatoid arthritis treatment

    Foster City, Calif., and Mechelen, Belgium; 19 December 2019, 22.30 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that its collaboration partner, Gilead Sciences, Inc. (NASDAQ:GILD) has submitted

  33. Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

     -- Study Primary Endpoint Was Not Met; Improvement in Multiple Measures of Fibrosis and Liver Injury Was Observed with Investigational Firsocostat and Cilofexor -- -- Regimens Were Well Tolerated and Safety Measures

  34. Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company's Second CAR T Cell Therapy

    -- Investigational KTE-X19 To Be First Chimeric Antigen Receptor (CAR) T Cell Therapy for Mantle Cell Lymphoma if Approved -- -- Filing for Kite's Second CAR T Therapy Marks Potential Expansion of Company's Cell

  35. Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma

    SANTA MONICA, Calif. and HAMILTON, Bermuda, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Kite, a Gilead Company (NASDAQ:GILD), and Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa") announced today that the companies have

  36. Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma

    -- Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta -- Kite, a Gilead Company (NASDAQ:GILD), and Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa") announced today that the

  37. Kite and the CIBMTR® Present Positive Findings From Real-World Use of Yescarta® (Axicabtagene Ciloleucel) in Relapsed or Refractory Large B-Cell Lymphoma

    -- Post-Marketing Study with a Larger Proportion of Older and More Difficult-to-Treat Patients Demonstrates Comparable Safety and Efficacy Data to ZUMA-1 Pivotal Trial -- -- Results Presented at the American Society

  38. Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma

    -- 93 Percent of Patients Treated with Investigational KTE-X19 Achieved Response, Including 67 Percent with a Complete Response -- -- Findings Support Regulatory Filings for Kite's Second CAR T Cell Therapy -- --

  39. Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment

    -- 47 Percent of Refractory Large B-cell Lymphoma Patients in ZUMA-1 Pivotal Phase 2 Cohorts Were Alive Three Years after a Single Infusion of Yescarta -- -- Separate Cohort Finds Earlier Steroid Use May Reduce Risk

  40. National AIDS Memorial Receives $2.4 Million Donation From Gilead Sciences to Support the AIDS Memorial Quilt as It Moves Home to San Francisco

    Grant Will Support the Transfer of The Quilt, its Programs and a New Public Education Initiative to Reach Communities Adversely Impacted by HIV Today, the National AIDS Memorial and Gilead Sciences, Inc. (NASDAQ:GILD)

  41. Industry Veterans Appointed to Head the Global Technical Operations and Clinical Development Organizations at Kite

    -- Charles Calderaro and Ken Takeshita, MD to Join Kite's Leadership Team -- Kite, a Gilead Company (NASDAQ:GILD), today announced two new additions to the company's leadership team. Charles Calderaro will join Kite as

  42. NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease

  43. NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease

  44. New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional

  45. Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy

    ─ Phase 1 Results Support Up to Six-month Dosing Interval and Advancement Into Later-Stage Clinical Trials ─ Gilead Sciences, Inc. (NASDAQ:GILD) today announced data on GS-6207, an investigational, novel, selective,

  46. Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019

    -- AI-Based Tools for Liver Histology Assessment Contribute to Gilead's Broader Efforts to Improve Understanding of NASH -- -- Data Support Utility of Noninvasive Tests (NITs) for Risk Stratification and Monitoring of

  47. Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019

    -- Data Demonstrate Reductions in Hepatocellular Carcinoma in Hepatitis B (HBV) Patients Treated with Vemlidy -- -- Improved Markers of Bone and Renal Safety Also Seen with Vemlidy in Separate Analysis of HBV Patients

  48. Galapagos increases share capital through warrant exercise by Gilead

    Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from a warrant exercise by Gilead. On 1 November 2019,

  49. Galapagos increases share capital through warrant exercise by Gilead

    Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from a warrant exercise by Gilead. On 1 November 2019,

  50. Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019

    -- Survival Data at Three Years in ZUMA-1 and Results from Study Cohort Evaluating Safety and Efficacy of Earlier Steroid Use with Yescarta® (axicabtagene ciloleucel) in Large B-cell Lymphoma to be Presented -- --

  51. Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP®

    – Results Continue to Demonstrate Statistically Significant Advantages of Descovy® Over Truvada® for Study Measurements of Bone and Renal Safety – Gilead Sciences, Inc. (NASDAQ:GILD) today announced 96-week results

  52. Gilead's Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials

    – Data from the Two 144-week Studies in Treatment-naïve Adults Living with HIV Presented at European AIDS Conference (EACS)– Gilead Sciences, Inc. (NASDAQ:GILD) today announced findings from two randomized,

  53. Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%

    Mechelen, Belgium; 1 November 2019; 21:01 CET – Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ:GILD), delivered an exercise notice to Galapagos NV ((Euronext &, NASDAQ:GLPG) in

  54. Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%

    Mechelen, Belgium; 1 November 2019; 21:01 CET – Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ:GILD), delivered an exercise notice to Galapagos NV ((Euronext &, NASDAQ:GLPG) in

  55. GILEAD AND GALAPAGOS TO PRESENT NEW DATA ON FILGOTINIB AT 2019 ACR/ARP ANNUAL MEETING

    New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases FOSTER CITY, Calif. and

  56. Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting

    New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases Gilead Sciences, Inc. (NASDAQ:GILD)

  57. GILEAD AND GALAPAGOS TO PRESENT NEW DATA ON FILGOTINIB AT 2019 ACR/ARP ANNUAL MEETING

    New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases FOSTER CITY, Calif. and

  58. Gilead Sciences Announces Fourth Quarter 2019 Dividend

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.63 per share of common stock for the fourth quarter of 2019. The dividend is payable on

  59. Gilead Sciences Announces Third Quarter 2019 Financial Results

    - Product Sales of $5.5 billion - - GAAP Loss of $0.92 per share - - Non-GAAP Diluted EPS of $1.75 per share - - Revised Full Year 2019 Guidance - Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results

  60. Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Andrew Dickinson has been appointed Chief Financial Officer (CFO), effective November 1. Mr. Dickinson currently serves as the company's Executive Vice President,

  61. Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis

    Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral,

  62. GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

      Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational

  63. GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

      Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational

  64. Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 2019

    -- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30

  65. Gilead Sciences Submits New Drug Application for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the New Drug Application (NDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis (RA) has

  66. Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Merdad Parsey, MD, PhD, will join the company as Chief Medical Officer, effective November 1. Dr. Parsey will be responsible for the company's global clinical

  67. Gilead Presents New Data From the Company's HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019

    - Results from DISCOVER Trial Provide Bone and Renal Safety Profile Data from Participants who Switched from Truvada for PrEP® to Descovy for PrEP™ - - Analysis Illustrates the Significant and Independent Impact of

  68. U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP)

    - Descovy Demonstrated Non-inferior Efficacy and an Improved Bone and Renal Safety Profile Compared with Truvada® in People at Risk for Sexually Acquired HIV Infection in a Global Phase 3 Trial - Gilead Sciences, Inc.

  69. Companies Seek an Innovative Solution to the Growing Cancer Rates

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World Cancer Research Fund (WCRF)

  70. Gene Therapy Treatments Offer Hope for Cancer Patients

    NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Recent developments in gene therapy hold out hope for the treatment of a wide range of diseases, including fatal lung cancer. Genprex Inc. (NASDAQ:GNPX) (GNPX Profile) is focused

  71. Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10

    Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Daniel O'Day, Gilead's Chairman and Chief Executive Officer, will participate in a fireside chat at the Morgan

  72. Alberta Provides Access to Biktarvy® for the Treatment of HIV

    Gilead Canada recognizes the Government of Alberta for providing access to new treatment for people living with HIV In 2017, Alberta accounted for 11.7 per cent of reported HIV cases in Canada1 In clinical trials,

  73. Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

    Foster City, Calif. and Mechelen, Belgium; 23 August 2019; 22.01 CET; regulated information –   Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the closing of the global

  74. Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

    Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019. This press release